Slide 1: SUJANI VASIREDDI Date:
Digitally signed by SUJANI SUJANI VASIREDDI VASIREDDI Date: 2025.11.03 14:24:05 +05'30' 1
Slide 2: Investor Presentation Q2 & H1 FY26
INVESTOR PRESENTATION Q2 & H1 FY26 2
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table Of Contents
Table Of • Q2 & H1 FY26 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward 4
Slide 5: Q2 & H1 FY26 Earnings
Q2 & H1 FY26 Earnings Section • Q2 & H1 FY26 Highlights 01 • • Key Metrics: Q2 & H1 FY26 Profit & Loss Statement • Financial Track Record • Shareholding Pattern 5
Slide 6: Q2 FY26 Highlights
Q2 FY26 Highlights Rs 1,045 Mn Rs 369 Mn Rs 263 Mn Margin 35.3% Total Income EBITDA PBT Rs 4.5 Rs 478 Mn Rs 199 Mn Margin 19.1% CAPEX (Cash EPS PAT Outflow) 6
Slide 7: H1 FY26 Highlights
H1 FY26 Highlights Rs 2,038 Mn Rs 723 Mn Rs 515 Mn Margin 35.5% Total Income EBITDA PBT Rs 8.7 Rs 545 Mn Rs 388 Mn Margin 19.0% Cash & Cash EPS PAT Equivalent* *Cash and Cash equivalents includes other bank balances 7
Slide 8: Key Metrics: Q2 FY26
Key Metrics: Q2 FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 22.3% 20.6% 17.1% YoY YoY YoY 19.9% 19.0% 35.8% 35.7% 35.3% 19.1% 5 854 993 1045 306 354 369 170 189 199 3.8 4.3 4.5 0 Q2FY25 Q1FY26 Q2FY
Slide 9: Key Metrics: H1 FY26
Key Metrics: H1 FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 26.6% 26.4% 25.5% YoY YoY YoY 40% 35.5% 35.5% 35% 30% 25% 19.2% 19.0% 20% 15% 1,610 2,038 572 723 309 388 7.0 8.7 10% H1FY25 H1FY26 H1FY2
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q2 FY26 Q1 FY26 QoQ(%) Q2 FY25 YoY (%) H1 FY26 H1 FY25 YoY (%) Revenue from Operations 1,018 976 847 1,994 1,596 Other Income 27 17 7 44 14 Total Income 1,045 993 5.2% 854 22.3% 2,038 1,610 26.6% Material and Testing Costs 201 188 182 389 325 Cost of lab se
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 36% 19% 36% 31% 33% 17% 19% 29% 15% 15% 11.2% 25% 25.1% 46.3% CAGR 18% CAGR 4% 10% CAGR 1,837 2,115 2,797 3,216 2,923 3,482 2,038 330 538 817 984 977 1,262 723 214 413 482 488 668 388 68 FY20 FY21
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th September 2025 Share Information as on 30th September 2025 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 3,145.92 % free-float 64.01% Others Promoters 58.8% 36.0% Free-float market cap (INR Cr) 2,013.58 Total Debt (INR Mn) 67.97 Cash & Cash E
Slide 13: Company Overview
Company Overview Section • Vimta at a Glance 02 • • Our Journey Our Offerings • Geographical Presence • Management 13
Slide 14: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 15: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 600,000+ ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,216 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 16: Our offerings
Our offerings Drug discovery and development services Food & Agri Testing Electronics & Electricals Testing Environment Testing & Consultancy 16
Slide 17: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 18: Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & • FSSAI, ISO 17025, BIS, APEDA, EIC
Slide 19: Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Locations 1 (Hyderabad) Accredit
Slide 20: Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & Regulatory • MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Approvals • Post pro
Slide 21: Geographical Presence
Geographical Presence Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore Food Electronics & Electrical Hyderabad (Headquarters) Pharma Environment 21
Slide 22: Key Management Team
Key Management Team Harriman Vungal S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Executive Director - Executive Chairman Managing Director Executive Director Chief Financial Officer Operations • Dr. S P Vasireddi is a Scientist – • Harita has close to 25 years of • Sreenivas’
Slide 23: Industry Landscape
Industry Landscape Section • Market Opportunity 03 • Factors Driving Industry Growth 23
Slide 24: Markets Opportunity (Global)
Markets Opportunity (Global) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 14,580 14,340 36,250 9,320 7,430 3,990 25,330 (USD Mn) 9,740 Global 6,250 2,550 2025 | 2030 2024 | 2034 2025 | 2030 2025 | 2030 2023 | 2030 24
Slide 25: Markets Opportunity (Indian)
Markets Opportunity (Indian) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 309 394 1,799 460 100 (USD Mn) Indian 185 293 211 832 50 2025 | 2030 2024 | 2030 2024 | 2033 2024 | 2030 2021 | 2028 25
Slide 26: Factors Driving Industry Growth
Factors Driving Industry Growth • Increasing demand for new drug • Surge in demand for certification innovations, growth in biologics and services of electrical & electronic vaccine products development, and increasing regulations in pharma and products, growing defence budgets biotech industry and
Slide 27: Our Competitive Advantage
Our Competitive Advantage Section • Our Position in the CRTO Landscape 04 • Our Strength 27
Slide 28: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Clinical Research Electronics & Electricals • #1 in India • Among the most reputed CROs in • One of the leading labs in • Customers – 90% of India top 20 India Southern India • 36% revenues from overseas • 75% of revenues from overseas Food Testin
Slide 29: Our Strengths
Our Strengths Infrastructure Innovations Knowledge Unparalleled lab Continuous addition Multi-disciplinary, infrastructure in the of services and knowledgeable, skilled country. Gold LEED evolving excellence and trained certified Vivarium manpower Customer Centricity Compliance Technology Long term
Slide 30: Way Forward
Way Forward Section • Our Key Growth Drivers & Strategies 05 30
Slide 31: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices Growth momentum Capacity expansions Operational excellence Good corporate governance in markets Service innovations Hiring right talent Risk management Growing d
Slide 32: Thank You
THANK YOU Vimta Labs Ltd. Registered Office Siva Kambhampati | Chief Financial Officer #142, IDA Phase 2 Cherlapally, Siva.Kambhampati@vimta.com Hyderabad Telangana, India. 500051 Ernst & Young Siddesh Chawan Advait Bhadekar NSE: VIMTALABS ISIN: INE579C01029 Siddesh.Chawan@in.ey.com Advait.Bhadekar@